News & Announcements
-
Placing
/**/ RNS Number : 3746O IQ-AI Limited 07 October 2021 7 October 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) Placing IQ-AI is pleased to announce that it has raised £620,000 through the placing of 12,400,000 new ordinary shares of 0.01p each in the Company (“Ordinary Shares”, the “Placing Shares”) at a price
-
EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
/**/ RNS Number : 5128M IQ-AI Limited 22 September 2021 22 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI LIMITED AWARDED EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective
-
IB Software Chosen for Accuracy and Automation
/**/ RNS Number : 0638M IQ-AI Limited 17 September 2021 17 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IB Software Chosen for Quantitative Accuracy and Automation IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF) today announced the sale of multiple licenses of Imaging Biometrics (IB) software for the automated generation of quantitative perfusion maps. The
-
Update on Phase 1 Clinical Trial
/**/ RNS Number : 3307L IQ-AI Limited 10 September 2021 September 10, 2021 IQ-AI Limited (“IQ-AI” or the “Company”) IQ-AI update on Phase I clinical trial and software sales IQ-AI Limited (LSE: IQAI, OTCQB: IQAIF) announces that the Gallium Maltolate phase I clinical trial will now commence towards the end of Q4
-
Board Changes
/**/ RNS Number : 4651K IQ-AI Limited 02 September 2021 2 September 2021 IQ-AI Limited (“IQ-AI” or the “Company”) Board Changes IQ-AI Limited (LSE: IQAI; OTCQB: IQAIF) announces that Brett Skelly has been appointed as a non-executive Director of the Company with immediate effect. Brett has been working in the financial